跳至主要内容
临床试验/IRCT20200318046812N2
IRCT20200318046812N2招募中3 期

Safety and efficacy of Hydroxychloroquine + Azithromycin + Naproxen + Prednisolone” and Hydroxychloroquine + Azithromycin + Naproxen” regimens in comparison with Hydroxychloroquine + kaletra” on the need for intensive care unit treatment in patients with COVID-19; a randomized, multicenter, parallel groups, open label study

Bagheiat-allah University of Medical Sciences0 个研究点目标入组 906 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
906

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
16 years 至 100 years(—)
性别
All

入选标准

  • Diagnosis of COVID-19 based on either ground glass appearance in chest CT scan or positive RTPCR test for COVID-19
  • Requiring hospitalization
  • Patient's age between 16 and 100 years
  • Signed informed consent form

排除标准

  • Past history of hospitalization or treatment in hospital for COVID-19 disease
  • Receiving other antiviral medications such as (Hydroxychloroquine, Kaletra, Ribavirin, Oseltamivir)
  • Uncontrolled diabetes
  • Chemotherapy in the past month
  • Taking immunosuppressive drugs
  • Chronic liver or renal failure
  • Taking daily systemic corticosteroids
  • GI bleeding
  • Pregnancy or Lactation
  • Uncontrolled bacterial infection

研究者

发起方
Bagheiat-allah University of Medical Sciences

相似试验